Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN IN DEXTROSE 5% vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels and causing venous and arterial dilation.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina,Acute myocardial infarction (to reduce preload and afterload),Heart failure (off-label use for acute decompensated heart failure),Hypertensive crisis (off-label use for severe hypertension)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Extensively metabolized in the liver by glutathione-dependent organic nitrate reductase, and to a lesser extent via cytochrome P450 (CYP3A4). Primary metabolite is 1,2-glyceryl dinitrate (active).
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
~60% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
Vd: 0.3 L/kg; reflects distribution into vascular smooth muscle and minimal tissue penetration.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Intravenous: 100%; sublingual: ~40% (first-pass hepatic metabolism); oral: <10% due to extensive first-pass effect.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No specific dose adjustment required for renal impairment; monitor for volume status and hypotension.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh Class A: No adjustment. Class B: Reduce initial dose by 50%. Class C: Avoid use or reduce initial dose by 75%.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Not FDA-approved for pediatric use. Limited data: IV infusion 0.25-0.5 mcg/kg/min, titrate to effect; max 5 mcg/kg/min.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Lower initial doses recommended due to increased sensitivity; start at 5 mcg/min IV or 0.3 mg sublingual; monitor for hypotension.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
NOT available in this formulation. Nitroglycerin products do not carry a black box warning.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension (severe hypotension may occur, especially with hypovolemia),Bradycardia and paradoxical tachycardia,Increased intracranial pressure (use cautiously in head trauma or intracranial hemorrhage),Tolerance to nitrates with prolonged use (intermittent dosing recommended),Methemoglobinemia (rare, risk with high doses or prolonged infusion),Drug interactions with phosphodiesterase inhibitors (e.g., sildenafil) causing severe hypotension
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase inhibitors (e.g., sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure,Constrictive pericarditis or cardiac tamponade,Severe hypotension (systolic BP < 90 mm Hg),Acute myocardial infarction with right ventricular involvement,Obstructive cardiomyopathy (relative contraindication)
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol; may cause severe hypotension and reflex tachycardia. No other significant food interactions.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Nitroglycerin is generally considered to have low teratogenic potential. In the first trimester, there is no evidence of increased risk of major congenital malformations from human data. However, animal studies are insufficient to rule out risk. During the second and third trimesters, nitroglycerin is used for tocolysis and management of hypertensive emergencies without documented fetal harm, but potential for maternal hypotension leading to reduced uteroplacental perfusion exists. Overall, FDA assigns category C (risk cannot be ruled out).
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Nitroglycerin is excreted into breast milk in minimal amounts; the M/P ratio is not established. Concentrations are likely too low to cause adverse effects in the nursing infant. Based on limited data, nitroglycerin is considered compatible with breastfeeding, but caution is recommended, especially in infants with cardiovascular instability.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered drug metabolism) may necessitate dose titration to effect. No standard dose adjustment is defined; clinicians should initiate at low doses and titrate based on maternal blood pressure and uterine perfusion. The typical starting dose of 5 mcg/min intravenous is appropriate, with incremental increases guided by clinical response. Avoid bolus doses to prevent hypotension.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
For IV nitroglycerin in D5W, use non-PVC tubing (light-sensitive) and inline filter; avoid abrupt discontinuation to prevent rebound hypertension; titrate to chest pain relief or hemodynamic parameters; monitor for hypotension and bradycardia; tolerance may develop after 24 hours of continuous infusion.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Report any chest pain, severe headache, or dizziness immediately.,Avoid alcohol consumption while on this medication.,Do not stop infusion suddenly without medical supervision.,Remain lying down if dizzy or lightheaded.,Inform all healthcare providers of nitroglycerin use.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN IN DEXTROSE 5% vs MONOKET, answered by our medical review team.
NITROGLYCERIN IN DEXTROSE 5% is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels and causing venous and arterial dilation.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN IN DEXTROSE 5% and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN IN DEXTROSE 5% is: Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN IN DEXTROSE 5% and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN IN DEXTROSE 5% is classified as Category C. Nitroglycerin is generally considered to have low teratogenic potential. In the first trimester, there is no evidence of increased risk of major congenital malformations from human. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.